From left, Seo Jung-jin, co-founder of Celltrion, and Kim Kang-lip, head of the Ministry of Food and Drug Safety, look at a sample of CT-P59, a coronavirus treatment candidate, at a Celltrion factory in Incheon on Monday.
Celltrion’s Covid-19 treatment candidate has been proven to speed up the recovery time for the infected in a Phase 2 clinical trial, according to the drug maker speaking at an academic conference on Wednesday.
Korea JoongAng Daily Sitemap
